



Baker IDI Research Online

<http://library.bakeridi.edu.au>

This is the postprint version of the work. It is the manuscript that was accepted by the journal following peer review. It does not include the publisher's layout and pagination.

Linderborg KM, Kaur G, Miller E, Meikle PJ, Larsen AE, Weir JM, Nuora A, Barlow CK, Kallio HP, Cameron-Smith D, Sinclair AJ. Postprandial metabolism of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic acid (EPA, 20:5n-3) in humans. Prostaglandins Leukot Essent Fatty Acids 2013;88(4):313-9.

<http://hdl.handle.net/11187/1568>

1 Postprandial metabolism of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic
2 acid (EPA, 20:5n-3) in humans

3

4 Kaisa M. Linderborg^{1,*}, Gunveen Kaur², Eliza Miller³, Peter J. Meikle⁴, Amy E. Larsen⁵,
5 Jacquelyn M. Weir⁴, Anu Nuora¹, Christopher K. Barlow⁴, Heikki P. Kallio¹, David Cameron-
6 Smith⁶ and Andrew J. Sinclair⁷

7

8 ¹ Department of Biochemistry and Food Chemistry, University of Turku, Finland

9 ² Institute of Sport, Exercise and Active Living (ISEAL), Victoria University, Melbourne,
10 Victoria, Australia

11 ³ School of Exercise and Nutrition Sciences, Deakin University, Burwood, Victoria, Australia

12 ⁴ Metabolomics Laboratory, Baker IDI Heart and Diabetes Institute, Victoria, Australia

13 ⁵ Department of Human Biosciences, Faculty of Health Sciences, La Trobe University
14 Bundoora, Victoria, Australia

15 ⁶ Liggins Institute, University of Auckland, New Zealand

16 ⁷ Metabolic Research Unit, School of Medicine, Deakin University, Victoria, Australia

17

18 * Corresponding author. Address: Department of Biochemistry and Food Chemistry, 20014
19 University of Turku, Finland. Email: kaisa.linderborg@utu.fi. Tel: +358 2 333 6874. Fax: +358
20 2 231 7666.

21

22 Running title Postprandial metabolism of docosapentaenoic acid

23

24

25 Abstract

26 The study of the metabolism of docosapentaenoic acid (DPA, 22:5n-3) in humans has been
27 limited by the unavailability of pure DPA and the fact that DPA is found in combination with
28 eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) in natural
29 products. In this double blind cross over study, pure DPA and EPA were incorporated in
30 meals served to healthy female volunteers. Mass spectrometric methods were used to study
31 the chylomicron lipidomics. Plasma chylomicronemia was significantly reduced after the
32 meal containing DPA compared with the meal containing EPA or olive oil only. Both EPA and
33 DPA were incorporated into chylomicron TAGs, while there was less incorporation into
34 chylomicron phospholipids. Lipidomic analysis of the chylomicron TAGs revealed the
35 dynamic nature of chylomicron TAGs. The main TAG species that EPA and DPA were
36 incorporated into were EPA/18:1/18:1, DPA/18:1/16:0 and DPA/18:1/18:1. There was very
37 limited conversion of DPA and EPA to DHA and there were no increases in EPA levels during
38 the 5 hour postprandial period after the DPA meal. In conclusion, EPA and DPA showed
39 different metabolic fates, and DPA hindered the digestion, ingestion or incorporation into
40 chylomicrons of the olive oil present in the meal.

41

42 Key words

43 n-3 polyunsaturated fatty acids (PUFA); docosapentaenoic acid (DPA); eicosapentaenoic acid
44 (EPA); docosahexaenoic acid (DHA); chylomicron; lipid metabolism

45

46

47

48 1. Introduction

49

50 The essential fatty acid alpha-linoleic acid (ALA, 18:3n-3) can be metabolized *in vivo* by
51 desaturation and elongation enzymes to form a series of polyunsaturated fatty acids (PUFA)
52 of the n-3 series. In addition to potentially being synthesised from ALA, eicosapentaenoic
53 acid (EPA, 20:5n-3), docosahexaenoic acid (DHA, 22:6n-3) and docosapentaenoic acid (DPA,
54 22:5n-3) are provided from diet, mainly from fish and fish oil products and to a lesser extent
55 from ruminant meats. Currently, there is much information on the metabolism of both EPA
56 and DHA, while less is known about the metabolism of DPA.

57

58 *In vivo*, DPA is formed by chain elongation of EPA by the action of fatty acid elongases 2 and
59 5, while the conversion of DPA to DHA requires an elongation to 24:5n-3 and desaturation
60 to 24:6n-3 before peroxisomal beta-oxidation to yield DHA. As recently reviewed, ALA
61 supplementation in humans generally leads to an increase in plasma EPA and DPA, but has
62 little or no effect on DHA levels [1].

63

64 Previous studies have demonstrated a significant elevation in the level of DPA in the
65 circulating lipid fractions when human subjects have received seal oil [2-4]. However, such
66 effects cannot be directly attributed to the consumption of DPA since it represents
67 approximately 5% of the fatty acids in seal oil with a higher level of EPA that has the
68 potential to generate considerable amounts of DPA via chain elongation.

69

70 The previous knowledge on the metabolism of pure DPA in humans is limited to our study
71 [5], where a supplementation of a total of 8 grams of pure DPA or EPA revealed that within
72 four days of supplementation, DPA and EPA demonstrated different and specific
73 incorporation patterns into plasma lipid classes and red blood cell phospholipids.

74

75 In rats, short-term supplementation with pure DPA has significantly increased the
76 concentration of DHA in liver and the concentration of EPA in the liver, heart and skeletal
77 muscle, presumably by the process of retroconversion [6]. The retroconversion from DPA to

78 EPA was especially apparent in the kidney of the rats [7]. The metabolism and the biological
79 effects of DPA have been recently reviewed [8].

80

81 Tandem mass spectrometric lipidomic methods enable us to study the composition of lipids
82 as they occur in the human plasma. This information is complimentary to the fatty acid
83 composition that requires the cleavage of the fatty acids from the molecules in which they
84 naturally occur. The lipidomic methods have previously revealed the non-steady state of
85 lipids in the postprandial state [9-11].

86

87 We hypothesized that pure DPA and EPA would have different postprandial metabolic fates.
88 To test this, a cross over study with healthy female volunteers and meals containing pure
89 EPA and pure DPA was designed. A meal that contained olive oil was used as a control.
90 Molecular level lipidomic analysis methods were used to investigate the structure and
91 composition of the lipids. Special interest was placed on the metabolism of the n-3 PUFA in
92 chylomicron triacylglycerols (TAG) and phospholipids.

93

94

95 2. Materials and Methods

96

97 2.1 Study design

98 Ten healthy normal weight females between the age of 20 to 30 took part in the
99 randomized cross over study with three different breakfast meals. The subjects had a BMI
100 between 20 to 25 kg/m² and their habitual total consumption of omega-3 polyunsaturated
101 fatty acids was not more than 0.5 grams per day as assessed from a food frequency
102 questionnaire [12, 13]. The baseline values for EPA and DHA proportions in their
103 erythrocytes were 1.0±0.1 and 6.7±0.6 per cent (mean±standard error of mean),
104 respectively. Subjects with any form of cardiovascular disease based on self-reported
105 medical status and family history were excluded from the study.

106

107 Following the postprandial study, the subjects consumed the study oil (olive, EPA or DPA) as
108 a one gram daily supplement for the subsequent six days after which the fasting blood lipids
109 were studied as described elsewhere [5]. After the end of the supplementation study, there
110 was a two-week wash out period prior to the next postprandial study. Throughout the study
111 weeks and the washout periods, the subjects were requested to refrain from consuming
112 products rich in long chain omega-3 PUFA including fish, red meat and omega-3 fortified
113 products (<2 marine and/or 2 red meat meals/week and <2 omega-3 fortified
114 products/week.

115

116 All subjects provided written informed consent. Ethics approval was obtained from the
117 Deakin University Human Research Ethics Committee (EC2011-023).

118

119 The night before each of the three study days, the participants consumed a standardized
120 dinner meal (containing pasta (dry 200 grams), tomato stir-through sauce (70 grams) and a
121 packet pudding) and were given instructions to fast overnight for 10 hours after the dinner.

122

123 The study breakfast consisted of 180 grams of instant mashed potato (Continental Deb™,
124 Unilever, Australasia) mixed with 70 milliliters boiled water and 20 grams of oil. In each of
125 the three meals, 18 grams of the 20 grams of oil consisted of olive oil (La Espanola Pure

126 Olive Oil, Seville, Spain). Additionally, the DPA breakfast included 2 grams of DPA (Equateq
127 Ltd, Breasclate, Callanish, Scotland), the EPA breakfast 2 grams of EPA (Equateq Ltd,
128 Breasclate, Callanish, Scotland) and the control (olive oil) meal an additional 2 grams of olive
129 oil. EPA and DPA were included in the olive oil as free fatty acids. The subjects could use salt,
130 pepper or chicken flavoured salt with the meal, which was consumed within 15minutes;
131 water was provided ad libitum throughout the five hour study period.

132

133 After the DPA meal, there were two cases of diarrhea and one case of upset stomach but no
134 diarrhea. One case of diarrhea was reported after the EPA meal, and there were no
135 complaints after the olive oil meal. All complaints occurred 2 to 3 hours after the breakfast.

136

137 2.2 Isolation of plasma and chylomicrons

138 Venous blood was drawn at the fasting state and thereafter hourly between one and five
139 hours postprandially. EDTA blood samples were immediately centrifuged for fifteen minutes
140 at 591 x g to isolate the plasma.

141

142 A chylomicron-rich fraction (Svedberg flotation unit (Sf) > 400), later abbreviated to
143 "chylomicrons", was isolated from plasma by ultracentrifugation using a Beckman ultra
144 centrifuge and TLA 100.4 rotor (Beckman instruments, Palo Alto, CA, USA) as previously
145 described [14]. Briefly 1.8 milliliters of EDTA plasma was overlaid with saline solution
146 (density = 1.006 kg/l) in ultracentrifuge tubes and centrifuged at 35,000 x g for 30 minutes
147 at 23°C. The top 1 millilitre was aspirated to remove the chylomicron-rich fraction. All
148 samples were frozen at -80°C prior analysis.

149

150 2.3 TAG concentration analysis

151 TAG concentrations in plasma and the isolated chylomicrons were measured on a Roche
152 Cobas Integra 400 plus autoanalyser (Roche, Laval, Quebec, Canada) by enzymatic
153 colorimetric method using commercially available kits (TRIGL) as per the manufacturer's
154 instructions (Roche, Laval, Quebec, Canada).

155

156 2.4 Fatty acid analysis

157 An internal standard mixture of triheptadecanoin (Sigma-Aldrich, St.Louis, MO, USA),
158 dinonadecanoylphosphatidylcholine (Sigma-Aldrich, St.Louis, MO, USA) and
159 cholesterylpentadecanoate (Nu-Chek Prep. Inc., Elysian, MN, USA) was added to the isolated
160 chylomicrons. Then 1.5 milliliters of methanol, 3 milliliters of chloroform and 0.8 milliliters
161 of 0.88 % KCl in water were added and the blend was thoroughly vortexed after each
162 addition. The tubes were centrifuged 2000 x g for 3 minutes to separate the layers, and the
163 chloroform rich layer was removed and evaporated to dryness [15]. TAGs and phospholipids
164 were isolated from the extracted lipid mixture with solid phase extraction based on silica
165 columns [16].

166

167 Fatty acid methyl esters (FAME) were prepared with a sodium methoxide method. In short,
168 the lipids were suspended to 1 milliliters of dry diethylether; then 25 microliters of
169 methylacetate and 25 microliters of sodium methoxide were added and the blend was
170 incubated for 5 minutes while shaken at times. The reaction was stopped with 6 microliters
171 of acetic acid. The tubes were centrifuged 2000 x g for 5 minutes, after which the
172 supernatant was removed and gently evaporated to dryness. The resulting FAME were
173 transferred to 100 microliter inserts in hexane [17]. The FAME were analysed with gas
174 chromatography (Shimadzu GC-2010 equipped with AOC-20i auto injector, flame ionization
175 detector (Shimadzu corporation, Kyoto, Japan) and wall coated open tubular column DB-23
176 (60 m x 0.25 mm i.d., liquid film 0.25 μm , Agilent technologies, J.W. Scientific, Santa Clara,
177 CA, USA). Splitless/split injection was used and the split was opened after 1 minute. Supelco
178 37 Component FAME Mix (Supelco, St. Louis, MO, USA), 68D (Nu-Check-Prep, Elysian, MN,
179 USA) and GLC-490 (Nu-Check-Prep, Elysian, MN, USA) were used as external standards.

180

181 2.5 Lipidomics

182 Lipidomic analysis of the one, three and five hour chylomicron samples was performed by
183 liquid chromatography, electrospray ionisation-tandem mass spectrometry using an Applied
184 Biosystems 4000 QTRAP mass spectrometer running Analyst 1.5 software. Liquid
185 chromatography was performed on a Zorbax C18, 1.8 micrometer, 50 x 2.1 millimeter
186 column (Agilent technologies, Santa Clara CA, USA). The lipids of the chylomicrons were
187 extracted with chloroform:methanol (2:1, 20 volumes), mixed, sonicated (30 minutes) and

188 allowed to stand for 20 minutes. Samples were centrifuged (16 000 x g, 10 minutes) and the
189 supernatant transferred to a 96 well PPE plate and dried until a stream of nitrogen at 40°C.
190 Immediately before analysis, samples were resuspended in water saturated butanol and
191 methanol containing 10 millimolar ammonium formate. The mobile phase was
192 tetrahydrofuran:methanol:water in a 30:20:50 ratio (A) and 75:20:5 (B) both containing 10
193 millimolar ammonium formate. TAG were separated with an isocratic flow (100 microliters
194 per minute) of 85% mobile phase B. Phospholipids and cholesteryl esters were separated by
195 a gradient from 0%B and 100%A to 100%B and 0%A over 8 minutes then held at 100%B for 2
196 minutes before equilibrating to starting conditions. Quantification of individual TAG species
197 was performed using scheduled multiple-reaction monitoring in the positive ion mode [18].
198 Lipid concentrations (picomoles per milliliter) were calculated by relating the peak area of
199 each species to the peak area of the internal standard of triheptadecanoin (Sigma Aldrich, St
200 Louis MO, USA) for TAGs, cholesteryl ester-18:0-d₆ (CDN isotopes, Quebec, Canada) for
201 cholesteryl esters, phosphatidyl choline-13:0/13:0 (Avanti Polar Lipids, Alabaster AL, USA)
202 for phosphatidyl cholines and phosphatidyl ethanolamine-17:0/17:0 (Avanti Polar Lipids,
203 Alabaster AL, USA) for ethanolamines and phosphatidyl inositols (using Multiquant 1.2
204 software). As no standards were available for each TAG species, no adjustment was made
205 for different response factors and the relative proportions of different species should be
206 taken as semi-quantitative. The MRM analysis of TAG species provides information on a
207 group of isomeric TAGs for which the sum of the fatty acid chain lengths and number of
208 double bonds is that same rather than the individual species. TAGs that were likely to
209 contain arachidonic acid, EPA, DPA or DHA were subjected to additional MRM analysis
210 monitoring the loss of neutral 16:0, 16:1, 18:1, 18:2, 18:3, 20:4, 20:5, 22:5 and 22:6.
211 Although these losses are known to not be strictly quantitative as the branching ratio
212 between different fragmentation channels is controlled by fatty acid position, chain length
213 and degree of unsaturation, this experiment provides an indication of the predominant
214 molecular species within each isomeric group. The most likely TAG fatty acid combinations
215 were estimated from the results.

216

217 2.6 Statistical analysis

218 Normal distribution of the data was tested with the Shapiro-Wilk test. Depending on the
219 normality of the data, paired samples t-test or Wilcoxon matched-pairs signed ranks test,
220 was used to compare the measured responses to control. ANOVA for repeated
221 measurements was used for multiple comparisons. Paired samples t-test or Wilcoxon
222 matched-pairs signed ranks test with Bonferroni correction was used for post hoc
223 comparisons. Statistical significance was indicated by $p < 0.05$. Statistical analyses were
224 performed with SPSS 18.0 software (SPSS Inc, Chicago, IL, USA).

225

226 3. Results

227 Chylomicron TAGs remained at almost fasting level after the DPA breakfast. The incremental
228 area under the chylomicron TAG curve after the DPA meal was significantly reduced when
229 compared with the corresponding area after the olive oil meal ($p=0.021$) or the area after
230 the EPA meal ($p=0.034$). In plasma, there was no significant difference between the TAG
231 areas under the curve after DPA meal and the olive oil control meal ($p=0.078$). Of the
232 individual time points, the TAG concentration was lower after the DPA breakfast at one and
233 two hours ($p=0.024$ and $p=0.014$ respectively, for plasma and $p=0.017$ and $p=0.068$
234 respectively, for chylomicrons) compared with the control meal (Figure 1).

235

236 At one to five hours postprandially, EPA was significantly higher in the chylomicron TAGs
237 after the breakfast containing EPA than after the breakfast containing olive oil only. The
238 difference in EPA was significant between the EPA meal and the DPA meal at 1 hour and
239 three to five hours (Figure 2). Correspondingly the DPA content was significantly higher after
240 the DPA breakfast than after the olive oil meal (2-5 hours, p value for the 3 hour difference
241 being 0.06) or after the EPA meal (3-5 hours). DPA did not raise the proportion of EPA in
242 chylomicron TAGs. DHA was increased after the DPA breakfast compared with the olive oil
243 breakfast at 2 hours and 3 hours, and increased after the EPA breakfast compared with the
244 olive oil breakfast at 5 hours (Fig 2). The largest difference in the CM TAG concentrations
245 after the three meals was at the one hour time point in which there was proportionally
246 more 16:0, 18:0 and 18:2n-6 and proportionally less 18:1n-9 in the chylomicron TAGs after
247 the DPA meal compared with the olive oil control meal (data not shown).

248

249 Chylomicron phospholipid fatty acid compositions were less affected by the meal compared
250 with chylomicron TAGs. At 2 hours, the proportion of EPA was increased after the EPA
251 breakfast compared with the two other breakfasts, and at 2 hours, the EPA breakfast also
252 increased the amount DPA and DHA compared to the olive oil breakfast (Fig 3). There were
253 no differences in the prevalences of the polyunsaturated fatty acids at other time points.

254

255 There were significant differences in the concentrations of TAGs containing PUFA between
256 the breakfast groups (Figure 4). The predominant species contributing to these groups of
257 TAGs were estimated through the use of more extensive multiple-reaction monitoring
258 experiments monitoring the neutral losses of fatty acids. The major species that contained
259 EPA after the EPA breakfast included 20:5/18:1/18:1 and 20:5/18:1/16:0. The overall
260 presence of DPA was lower than that of EPA as seen also from the TAG concentration and
261 fatty acid composition data. The major TAGs containing PUFA after the DPA breakfast were
262 22:5/18:1/16:0, 22:5/18:2/18:1 and 22:5/18:1/18:1. TAG 54:5, mostly 20:4/18:1/16:0, was
263 detected in equal amounts after all meals.

264

265 Although very modest in the overall response, some conversion to DHA was apparent in the
266 TAG 58:9 (mostly 22:6/18:2/18:1) as there was significantly more of this TAG after the EPA
267 and DPA breakfasts compared with the olive oil breakfast at the 3 and 5 hour time points.
268 Apart from the PUFA containing TAGs presented in Figure 4, TAGs 18:1/18:1/16:0,
269 18:1/18:1/18:1 and 18:2/18:1/16:0 were abundant TAGs after all meals (data not shown).

270

271 DPA containing TAGs were less abundant at one hour postprandially compared with the
272 three and five hour time points indicating that their digestion was delayed compared with
273 the EPA containing TAGs. This was seen also in the fatty acid composition data.

274

275 Of the phospholipid species measured, phosphatidyl cholines were the most abundant
276 phospholipid species in chylomicrons followed by inositols, ethanolamines and serines as
277 measured with HPLC-MS/MS (data not shown). There were no between-breakfast
278 differences in the individual phospholipids or clear increasing or decreasing trends within
279 the measured time points.

280

281 No differences were found in chylomicron cholesteryl esters species between breakfasts or
282 between the three measured time points (1, 3 and 5 hours) (data not shown). The most
283 abundant fatty acid in chylomicron cholesteryl esters was 18:2 followed by 16:0, 18:1 and
284 20:4 in about equal amounts and then by 16:1, 18:3, 20:5 and 22:6.

285

286 4. Discussion and Conclusions

287 DPA is an elongated metabolite of EPA and it is one of the intermediate products between
288 EPA and DHA. The present study investigated the postprandial metabolism of pure DPA and
289 EPA in an olive oil containing meal.

290

291 The major finding in this study is that the addition of 2 grams of DPA to the 18 grams of olive
292 oil almost completely eliminates the incorporation of fatty acids in chylomicrons within five
293 hours. In contrast, this effect was not seen with the addition of EPA.

294

295 One of the possible potential mechanisms that can explain the decreased chylomicronemia
296 caused by DPA could be that DPA was acting as a pancreatic lipase inhibitor. If DPA did
297 hinder the action of the lipase, the result would be a reduced or slower chylomicronemia
298 and there would be reduced levels of chylomicron TAGs, particularly those with oleic acid
299 (from the 18 gram of fed olive oil). Both of these effects were observed in this study.
300 Furthermore, if some of the fat ingested was not thoroughly or efficiently digested by the
301 lipase, some of the fat would be malabsorbed and lost in the feces. This hypothesis is
302 supported by the recorded observation that three out of the ten subjects reported diarrhea
303 or upset stomach in the three hours following the DPA breakfast.

304

305 Another possible explanation relates to the TAG reservoirs that are known to exist in
306 enterocytes [19]. It might be that the lipids of the DPA breakfast were stored in the
307 enterocytes and released either over a longer time span than the five hours that were
308 followed in this study or after the following meal.

309

310 Other possible mechanisms e.g. ones involving bile salts, absorption into mucosal cells,
311 disruption of TAG synthesis or the packaging of chylomicron, and enhancement of

312 chylomicron clearance are also possible. However, the diarrhea observed by some of the
313 subjects supports effects taking place in the gut rather than in the mucosal cells or blood.

314

315 The beneficial effects of long-term fish oil supplementation on lowering plasma TAGs has
316 been well documented, but the underlying mechanisms remain poorly defined [20]. It has
317 been suggested that n-3 fatty acids could enhance postprandial chylomicron clearance
318 through reduced VLDL secretion and by directly stimulating the activity of lipoprotein lipase
319 [21, 22]. The VLDL rich lipoprotein fraction was not collected in this study, however, no
320 significant difference ($p=0.078$) was seen in the areas under the plasma TAG curves, possibly
321 due to higher variation in between-subject plasma TAG concentrations than in chylomicron
322 TAG concentrations. EPA and DHA supplementation have equally effectively decreased
323 chylomicron particle sizes and accelerated chylomicron triacylglycerol clearance [23], while
324 the effect of DPA has not been studied before.

325

326 The bioavailability of EPA or DHA as free fatty acids has not differed from natural TAGs in
327 previous studies [24]. Also, the absorption of EPA and DHA supplementation in plasma
328 appears to be similar to each other but varies with the form in which fatty acids are
329 supplemented. Lawson and Hughes [25] reported that as free acids, both EPA and DHA were
330 well absorbed (up to 95%) while the TAGs form of EPA and DHA were absorbed almost as
331 well as the free acids. The ethyl esters of EPA and DHA on the other hand, were relatively
332 poorly absorbed. However, DPA has not been administered previously in postprandial
333 human studies as a free fatty acid or other form so the potential route of absorption as a
334 free fatty acid bound to albumin for DPA should be looked for in the future studies. We did
335 not find indications of selective loss of certain FA over others. The likely explanation for the
336 differences in the chylomicron TAG FA composition of the one hour time point after the
337 different meals is that the endogenous lipids are represented in greater proportions in the
338 chylomicron TAGs after the DPA meal than after the olive oil meal. However, in further
339 studies the possible selectivity in the loss of different FA should be looked into for example
340 by analyzing the composition of fecal lipids.

341

342 Despite differences in the total amount of lipids absorbed or the absorbance rates, both
343 DPA and EPA were transported in the chylomicron TAGs rather than in chylomicron
344 phospholipids over the five hour period followed. Previously it has been found that linoleic
345 acid was proportionally incorporated more into chylomicron phospholipids and cholesteryl
346 esters than oleic or palmitic acids at four and seven hours postprandially [26].

347

348 New tools for fighting the growing prevalence of obesity worldwide are needed. Currently
349 orlistat, a lipase inhibitor, is the only available long-term treatment for obesity. In the past
350 years, numerous drugs have been approved for the treatment of obesity; however, most of
351 them like amphetamine, rimonabant and sibutramine have been withdrawn from the
352 market because of their adverse effects [27]. Should DPA prove to have potential as an
353 agent that decreases postprandial lipemia, side effects other than steatorrhea need to be
354 considered. The n-3 PUFA have multiple cardiovascular benefits including inhibition of
355 platelet aggregation [28]. This might pose a side effect of increasing bleeding risk. However,
356 in a recent report of a large cohort of more than 1500 patients with acute myocardial
357 infarction no relation was found between the omega-3 index and bleeding [29].

358

359 In population studies DPA has been associated positively with cardiovascular health. A
360 higher level of DPA in the circulation has been associated with a lower risk of coronary heart
361 disease [30], and a higher intake of DPA and a higher level of DPA in circulation have been
362 associated with the protection against carotid atherosclerosis [31]. These findings may in
363 part be mediated via the lowered postprandial chylomicronemia, as an increased
364 postprandial plasma TAG level is a risk factor for cardiovascular diseases [32-34]. However,
365 n-3 PUFA exert their cardioprotective effects through multiple mechanisms, including
366 reducing arrhythmias or altering production of prostaglandins, which reduces inflammation
367 and improves platelet and endothelial function [35]. Indeed, DPA has shown the ability to
368 inhibit human platelet aggregation in vitro and to suppress thromboxane formation [36]. It
369 has been postulated that due to its high DPA content as well as high EPA content, seal oil

370 may be even more efficient than fish oil at promoting healthy plasma lipid profiles and
371 lowering thrombotic risk [4].

372

373 Our current understanding of the role of TAGs in human nutrition largely comes from the
374 measurement of either the concentration of TAGs or from the fatty acid composition, which
375 requires the release of the fatty acids from the TAGs. In this study, molecular level tandem
376 mass spectrometric lipidomic analysis method was used to identify and study the TAG
377 species present in chylomicrons. In addition to identifying the most abundant EPA and DPA
378 containing TAGs, the non steady state of the chylomicron lipid molecules over the
379 postprandial period was revealed. Although in the current study the major difference in the
380 TAG composition was between the one hour time point compared with the three and five
381 hour time points, it supports previous studies [9 -11] where the composition of
382 chylomicrons has not been constant during the postprandial state. This indicates that
383 different TAGs may be formed and/or cleared in favour of others.

384

385 Whether the individual long chain n-3 PUFA have shared or complimentary effects is not
386 well established due to the challenges in obtaining pure DPA for research purposes. Overall,
387 for many cardiovascular pathways and outcomes, identified studies of individual
388 polyunsaturated fatty acids are limited, especially for DPA [37]. The data presented in this
389 manuscript indicates that EPA and DPA are metabolized differently postprandially. The
390 lipidomic analysis of the postprandial fate of DPA as well as the reduced chylomicronemia
391 observed in this study, invite long term human trials with pure DPA, further postprandial
392 trials with larger lipid loads and different forms of DPA as well as *in vivo* and *in vitro* studies
393 of the mechanisms involved.

394

395 5. Acknowledgements

396 Dr Andrew Garnham is thanked for medical support and Dr Marissa Caldwell for clinical trial
397 support. Equateq Ltd (UK) is acknowledged for the generous provision of the pure

398 supplements. Meat & Livestock Australia and Deakin University Strategic Research Centre
399 for Molecular Medicine are acknowledged for their financial support. Osk. Huttunen
400 Foundation and Finnish Food Research Foundation are acknowledged for support to Dr
401 Linderborg. Finally we wish to acknowledge and thank our participants.

402

403 Conflict of interest

404 The authors declare no conflict of interest.

405

406

407

408 References

409

- 410 1. J.T. Brenna, N. Salem Jr, A.J. Sinclair, S.C. Cunnane, Alpha-Linolenic acid
411 supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in
412 humans, *Prostaglandins Leukot Essent Fatty Acids* 80 (2009) 85-91.
- 413 2. J.A. Conquer, L.A. Cheryk, E. Chan, P.A. Gentry, B.J. Holub, Effect of supplementation
414 with dietary seal oil on selected cardiovascular risk factors and hemostatic variables
415 in healthy male subjects, *Thromb Res* 96 (1999) 239-250.
- 416 3. B.J. Meyer, A.E. Lane, N.J. Mann, Comparison of seal oil to tuna oil on plasma lipid
417 levels and blood pressure in hypertriglyceridaemic subjects, *Lipids* 44 (2009) 827-
418 835.
- 419 4. N.J. Mann, S.L. O'Connell, K.M. Baldwin, I. Singh, B.J. Meyer, Effects of seal oil and
420 Tuna-fish oil on platelet parameters and plasma lipid levels in healthy subjects, *Lipids*
421 45 (2010) 669-681.
- 422 5. E. Miller, G. Kaur, A. Larsen, S.P. Loh, K. Linderborg, H.S. Weisinger, G. Turchini, D.
423 Cameron-Smith, A.J. Sinclair, A short-term n-3 DPA supplementation study in
424 humans, *Eur J Nutr* (2012) doi: DOI 10.1007/s00394-012-0396-3.
- 425 6. G. Kaur, D.P. Begg, D. Barr, M. Garg, D. Cameron-Smith, A.J. Sinclair, Short-term
426 docosapentaenoic (22:5 n-3) supplementation increases tissue docosapentaenoic
427 acid, DHA and EPA concentration in rats, *Br J Nutr* 130 (2010) 32-37.
- 428 7. B.J. Holub, P. Swidinsky, E. Park, Oral docosapentaenoic acid (22:5n-3) is
429 differentially incorporated into phospholipid pools and differentially metabolized to
430 eicosapentaenoic acid in tissues from young rats, *Lipids* 46 (2011) 399-407.
- 431 8. G. Kaur, D. Cameron-Smith, M. Garg, A.J. Sinclair, Docosapentaenoic acid (22:5n-3): a
432 review of its biological effects, *Prog Lipid Res* 50 (2011) 28-34.
- 433 9. R. Abia, J.S. Perona, Y.M. Pacheco, E. Montero, F.J. Muriana, V. Ruiz-Gutierrez,
434 Postprandial triacylglycerols from dietary virgin olive oil are selectively cleared in
435 humans, *J Nutr* 129 (1999) 2184-2191.
- 436 10. K.M. Yli-Jokipii, U.S. Schwab, R.L. Tahvonen, J.-P. Kurvinen, H.M. Mykkänen, H.P.T.
437 Kallio, Triacylglycerol molecular weight and to a lesser extent, fatty acid positional
438 distribution, affect chylomicron triacylglycerol composition in women, *J Nutr* 132
439 (2002) 924-929.
- 440 11. K.M. Yli-Jokipii, U.S. Schwab, R.L. Tahvonen, J.-P. Kurvinen, H.M. Mykkänen, H.P.T.
441 Kallio, Chylomicron and VLDL TAG structures and postprandial lipid response induced
442 by lard and modified lard, *Lipids* 38 (2003) 693-703.

- 443 12. B. Sullivan, P. Williams, B. Meyer, Biomarker validation of a new food frequency
444 questionnaire that estimates long-chain omega-3 polyunsaturated fatty acids, *Lipids*
445 41 (2006) 845-850.
- 446 13. M. Swierk, P. Williams, B. Meyer, J. Wilcox, K. Russel, Validation of an Australian
447 electronic food frequency questionnaire to measure polyunsaturated fatty acid
448 intake, *Nutr* 6 (2011) 641-646.
- 449 14. J.J. Ågren, M. Hallikainen, H. Vidgren, T.A. Miettinen, H. Gylling, Postprandial lipemic
450 response and lipoprotein composition in subjects with low or high cholesterol
451 absorption efficiency, *Clin Chim Acta* 366 (2006) 309-315.
- 452 15. J. Folch, M. Lees, G.H.S. Stanley, A simple method for the isolation and purification of
453 total lipides from animal tissues, *J Biol Chem* 226 (1957) 497-509.
- 454 16. J.G. Hamilton, K. Comai, Rapid separation of neutral lipids, free fatty acids and polar
455 lipids using prepacked silica Sep-Pak columns, *Lipids* 23 (1988) 1146-1149.
- 456 17. W.W. Christie, A simple procedure for rapid transmethylation of glycerolipids and
457 cholesteryl esters, *J Lipid Res* 23 (1982) 1072-1075.
- 458 18. R.C. Murphy, P.F. James, A.M. McAnoy, J. Krank, E. Duchoslav, R.M. Barkley,
459 Detection of the abundance of diacylglycerol and triacylglycerol molecular species in
460 cells using neutral loss mass spectrometry, *Anal Biochem* 366 (2007) 59-70.
- 461 19. J.E. Lambert, E.J. Parks, Postprandial metabolism of meal triglyceride in humans.
462 *Biochim Biophys Acta*, 1821 (2012) 721-726.
- 463 20. C. Xiao, G.F. Lewis Regulation of chylomicron production in humans. *Biochim Biophys*
464 *Acta* 1821 (2012) 736-746.
- 465 21. M.H. Davidson, Mechanisms for hypotriglyceridemic effect of marine omega-3 fatty
466 acids, *Am J Cardiol* 96 (2006) 27i-33i.
- 467 22. H.E. Bays, A.P. Tighe, R. Sadovsky, M.H. Davidson Prescription omega-3 fatty acids
468 and their lipid effects: physiologic mechanisms of action and clinical implications,
469 *Expert Rev Cardiovasc Ther* 6 (2008) 391-409.
- 470 23. Y. Park, W.S. Harris, Omega-3 fatty acid supplementation accelerates chylomicron
471 triglyceride clearance, *J Lipid Res* 44 (2003) 455-463.
- 472 24. J. Dyerberg, P. Madsen, J.M. Moller, I. Aardestrup, E.B. Schmidt, Bioavailability of
473 marine n-3 fatty acid formulations, *Prostaglandins Leukotrienes Ess Fatty Acids* 83
474 (2010) 137-141.
- 475 25. L.D. Lawson, B.G. Hughes Human absorption of fish oil fatty acids as triacylglycerols,
476 free acids, or ethyl esters. *Biochem Biophys Res Comm* 15 (1988) 328-35.

- 477 26. L. Hodson, S.E. McQuaid, F. Karpe, K.N. Frayn, B.A. Fielding, Differences in
478 partitioning of meal fatty acids into blood lipid fractions: a comparison of linoleate,
479 oleate, and palmitate, *Am J Physiol Endocrinol Metab* 296 (2009) E64-71.
- 480 27. J.G. Kang, C.-Y. Park, Anti-obesity drugs: A review about their effects and safety,
481 *Diabetes Metab J* 36 (2012) 13-25.
- 482 28. M. Phang, A.J. Sinclair, L.F. Lincz, M.L. Garg, Gender-specific inhibition of platelet
483 aggregation following omega-3 fatty acid supplementation, *Nutr Metab Cardiovasc*
484 *Dis* 22 (2012) 109-114.
- 485 29. A.C. Salisbury, W.S. Harris, A.P. Amin, K.J. Reid, J.H. O'Keefe, J.A. Spertus,
486 Relation between red blood cell omega-3 fatty acid index and bleeding during acute
487 myocardial infarction, *Am J Cardiol* 109 (2012) 13–18.
- 488 30. J.A. Simon, M.L. Hodgkins, W.S. Browner, J.M. Neuhaus, J.T. Bernert Jr, S.B.
489 Hulley, Serum fatty acids and the risk of coronary heart disease, *Am J Epidemiol* 142
490 (1995) 469-476.
- 491 31. A. Hino, H. Adachi, K. Toyomasu, N. Yoshida, M. Enomoto, A. Hiratsuka, Y. Hirai,
492 A. Satoh, T. Imaizumi, Very long chain N-3 fatty acids intake and carotid
493 atherosclerosis: an epidemiological study evaluated by ultrasonography,
494 *Atherosclerosis* 176 (2004) 145-149.
- 495 32. J. O'Keefe, D. Bell, The post-prandial hyperglycemia/hyperlipemia hypothesis: a
496 hidden cardiovascular risk factor? *Am J Cardiol* 100 (2007) 899-904.
- 497 33. A.C.I. Boullart, J. de Graaf, A.F. Stalenhoef, Serum triglycerides and risk of
498 cardiovascular disease, *Biochim Biophys Acta* 1821 (2012) 867–875.
- 499 34. K.G. Jackson, S.D. Poppitt, A.M. Minihane, Postprandial lipemia and
500 cardiovascular disease risk: Interrelationships between dietary, physiological and
501 genetic determinants, *Atherosclerosis* 220 (2012) 22-33.
- 502 35. A.P. DeFilippis, M.J. Blaha, T.A. Jacobson, Omega-3 Fatty Acids for Cardiovascular
503 Disease, *Prevention Curr Treat Options Cardiovasc Med* 12 (2010) 365-380.
- 504 36. L.A. Cheryk, J.A. Conquer, B.J. Holub, P.A. Gentry, Docosahexaenoic acid and
505 docosapentaenoic acid incorporation into human platelets after 24 and 72 hours:
506 inhibitory effects on platelet reactivity, *Platelets* 10 (1999) 203-211.
- 507 37. D. Mozaffarian, J.H.Y. Wu, (n-3) Fatty acids and cardiovascular health: Are effects
508 of EPA and DHA shared or complimentary?, *J Nutr* 142 (2012) 614S-625S.
509
510
511

Fig. 1 Triacylglycerol concentrations (mmol/l +/- standard deviation, n=10) in plasma (A) and chylomicron rich fraction (B) after the meals containing olive oil (open circles), or olive oil together with EPA (closed rectangles) or DPA (closed triangles) up to five hours postprandially. The incremental area under the curve differed significantly between the olive oil meal and the DPA meal in chylomicrons ($p=0.021$), but no such difference was found in plasma ($p=0.078$). Significant differences ($p < 0.05$) in individual time points between the olive oil breakfast and the DPA breakfast are marked by an asterisk




Fig. 2 Chylomicron triacylglycerol fatty acids (20:4n-6, 20:5n-3, 22:5n-3 and 22:6n-3) one to five hours postprandially after meals containing olive oil only (olive, white bars) or olive oil mixed with eicosapentaenoic acid (EPA, grey bars) or docosapentaenoic acid (DPA, black bars). Series of bars represent the times at which the blood was drawn (1 to 5 hours) and an asterisk a significant between meal difference in the corresponding time point. Values are mass proportions (mean +/- standard deviation, n=10) of all chylomicron triacylglycerol fatty acids




Fig. 3 Chylomicron phospholipid fatty acids (20:4n-6, 20:5n-3, 22:5n-3 and 22:6n-3) one to five hours postprandially after meals containing olive oil only (olive, white bars) or olive oil mixed with eicosapentaenoic acid (EPA, grey bars) or docosapentaenoic acid (DPA, black bars). Series of bars represent the times at which the blood was drawn (1 to 5 hours) and an asterisk a significant between meal difference in the corresponding time point. Values are mass proportions (mean +/- standard deviation, n=10) of all chylomicron phospholipid fatty acids




Fig. 4 PUFA containing triacylglycerols (acyl carbon number : number of double bonds) after the breakfasts containing olive oil (white bars), olive oil mixed with eicosapentaenoic acid (EPA, 20:5n-3, grey bars) and olive oil mixed with docosapentaenoic acid (DPA, 22:5n-3, black bars) at one, three and five hours , respectively. Semiquantitative values are expressed as molar percentages (mean +/- standard deviation, n=10) of all chylomicron TAGs. Most prevalent triacylglycerols based on the neutral loss experiments are marked above each group of bars.

